# Montelukast-Model
Whole-body PBPK model of montelukast

<p align="center">
  <img src="Montelukast.png">
</p>

## Repository files

Within this repository, we distribute a whole-body PBPK model of  Montelukast, that has been developed using clinical studies in adults and evaluated for its predictive performance of CYP2C8 mediated clearance after oral administration in children. 

The PK-Sim project file contains simulations of all published clinical studies employed during model establishment [[1-4](#reference)] and for model predictions in pediatrics [[1, 5-10](#reference)], including the respective observed data digitized.

Due to the large size of the PK-Sim project file, only the [_project snapshot_](https://docs.open-systems-pharmacology.org/working-with-pk-sim/pk-sim-documentation/importing-exporting-project-data-models#exporting-project-to-snapshot-loading-project-from-snapshot) file ['Montelukast.json'](Montelukast.json) has been published here. The pk-sim project file can be found under the ['releases'](../../releases) section.

## Code of conduct

Everyone interacting in the Open Systems Pharmacology community  (codebases, issue trackers, chat rooms, mailing lists etc...) is  expected to follow the Open Systems Pharmacology [code of conduct](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODE_OF_CONDUCT.md#contributor-covenant-code-of-conduct).

## Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the [contribution guidelines](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CONTRIBUTING.md#ways-to-contribute). If you are contributing code, please be familiar with the [coding standard](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODING_STANDARDS.md#visual-studio-settings).

## License

The model code is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).

## Reference

[1] [Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol. 2000 Sep;106(3 Suppl):S171-8.](https://www.ncbi.nlm.nih.gov/pubmed/10984399)

[2] [Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, Cheng H. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.Biopharm Drug Dispos. 1997 Dec;18(9):769-77.](https://www.ncbi.nlm.nih.gov/pubmed/9429741)

[3] [Fey C, Thyroff-Friesinger U, Jones S. Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy. 2014 Sep 18;4:29. doi: 10.1186/2045-7022-4-29. eCollection 2014.](https://ctajournal.biomedcentral.com/articles/10.1186/2045-7022-4-29)

[4] [Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996 Mar;13(3):445-8.](https://www.ncbi.nlm.nih.gov/pubmed/8692739)

[5] [Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):343-51.](https://insights.ovid.com/pubmed?pmid=15076638)

[6] [Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, Knorr B, Reiss TF. Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. J Clin Pharmacol. 2008 Apr;48(4):502-11. doi: 10.1177/0091270008314251. Epub 2008 Feb 22.](https://accp1.onlinelibrary.wiley.com/doi/full/10.1177/0091270008314251)

[7] [Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, Rogers JD, Zhang J, Larson P, Spielberg S. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol. 2001 Jun;41(6):612-9.](https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912700122010492?sid=nlm%3Apubmed)

[8] [Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P, Blake K, van Nispen CH, Noonan G, Freeman A, Haesen R, Michiels N, Rogers JD, Amin RD, Zhao J, Xu X, Seidenberg BC, Gertz BJ, Spielberg S. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol. 1999 Aug;39(8):786-93.](https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922008434?sid=nlm%3Apubmed)

[9] [Knorr B, Maganti L, Ramakrishnan R, Tozzi CA, Migoya E, Kearns G. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. J Clin Pharmacol. 2006 Jun;46(6):620-7.]()

[10] [Migoya E1, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA, Knorr B, Deutsch P. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol. 2004 May;44(5):487-94.](https://accp1.onlinelibrary.wiley.com/doi/full/10.1177/0091270004264970)





